[signal.]portfolio & asset diligence

Org: Demo Translational Institute — structured asset diligence, not investment advice.

← Portfolio

CFTR Corrector Triple Combination

Edit / manage →

Cystic fibrosis

Phase 3LicensedSmall moleculePulmonarySupportive· high conf3 evidence-linked claims2 snapshots

Overview

Disease area
Pulmonary
Indication
Cystic fibrosisMONDO:0009061
Mechanism of action
CFTR corrector/potentiator restoring channel gating
Development stage
Phase 3
Institution
Summit Pulmonary Research Group
Principal investigators
M. Castellano, P. Adeyemi
Targets
CFTR
Pathways
CFTR processing

Intake & funding

Applications

None recorded.

Funding events
  • awardUSD2,000,000Late-stage financing2024-02-01

Timeline

state through time · newest first
  1. Q4 2024Pre-commercial
    Milestones
    • ·Topline Phase 3 readout positive
    Accomplishments
    • ·Statistically significant ppFEV1 improvement
    Challenges
    • ·Payer positioning vs entrenched standard of care
    Next steps
    • ·File NDA
    • ·Build market-access dossier
    Risk themes:ReimbursementNarrow eligible population
  2. Q3 2024Late-stage financing secured
    Milestones
    • ·Phase 3 enrollment completed
    Accomplishments
    • ·Sweat chloride reductions consistent with mechanism
    Challenges
    • ·Differentiation limited to rare non-F508del genotypes
    Next steps
    • ·Database lock
    • ·Prepare regulatory submission
    Risk themes:Incumbent market dominance

Scientific assessment

1 claims
  • Supporting EvidenceStrong

    Triple corrector/potentiator combinations restore F508del-CFTR processing and channel gating with large ppFEV1 gains in late-phase studies.

    trialNCT01140451· 2019-10-31

Translational assessment

1 claims
  • EndpointsStrong

    Sweat chloride and ppFEV1 are established, regulator-accepted endpoints enabling efficient trial designs.

    trialNCT00112359

Regulatory assessment

0 claims

No evidence linked yet.

Commercial assessment

1 claims
  • Competitive LandscapeModerate

    Incumbent dominates CFTR modulation; entry thesis depends on rare non-F508del genotypes and improved tolerability.

    internalcomp-2024

Execution assessment

0 claims

No evidence linked yet.

Structured reviews

1 reviews
Supportive· high confExternalPulmonology KOL2024-12-05
Strengths

Positive Phase 3 on accepted endpoints; mechanism well understood.

Weaknesses

Addressable population narrow vs incumbent.

Improvement areas

Build payer and access strategy early.

Internal rubric input (reviewer scoring — not a success probability)
Scientific validity
Translational readiness
Regulatory pathway
Commercial potential
Execution strength

Outcome

  • Licensed
    Out-licensed to a respiratory pharma partner after positive Phase 3.2025-01-20

AI brief

flag off · defaultPhase 7

Runtime AI features are flag-gated and disabled by default. Set SIGNAL_LLM_ENABLED=1 (plus a provider key) to enable a grounded, source-cited brief generated from this asset's structured records — with forbidden-phrase and grounding validators enforcing no probability-of-success or buy/sell language.

Evidence tiers and reviewer rubric scores are internal, qualitative inputs — [signal.] surfaces never show a numeric probability of success or buy/sell language.